Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents

  • Andishe Attarbaschi
  • Elisa Carraro
  • Leila Ronceray
  • Mara Andrés
  • Shlomit Barzilai-Birenboim
  • Simon Bomken
  • Laurence Brugières
  • Birgit Burkhardt
  • Francesco Ceppi
  • Alan K S Chiang
  • Monika Csoka
  • Alina Fedorova
  • Janez Jazbec
  • Edita Kabickova
  • Jan Loeffen
  • Karin Mellgren
  • Natalia Miakova
  • Olga Moser
  • Tomoo Osumi
  • Apostolos Pourtsidis
  • Charlotte Rigaud
  • Anne Uyttebroeck
  • Wilhelm Woessmann
  • Marta Pillon
  • European Intergroup for Childhood Non-Hodgkin’s Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group

Abstract

Data on the spectrum of second malignant neoplasms (SMNs) after primary childhood non-Hodgkin's lymphoma (NHL) are scarce. One-hundred-and-eighty-nine NHL patients diagnosed in a 30 years period of 1980-2010 developing an SMN were retrieved from 19 members of the European Intergroup for Childhood NHL and/or the international Berlin-Frankfurt-Münster Study Group. Five subgroups of SMNs were identified: (1) myeloid neoplasms (n = 43; 23%), (2) lymphoid neoplasms (n = 51; 27%), (3) carcinomas (n = 48; 25%), (4) central nervous system (CNS) tumors (n = 19; 10%), and (5) "other" SMNs (n = 28; 15%). In 37 patients (20%) preexisting disorders were reported with 90% having any kind of cancer predisposition syndrome (CPS). For the 189 primary NHL patients, 5-year overall survival (OS) after diagnosis of an SMN was 56 ± 4%, being worst for patients with preexisting disorders at 28 ± 8%. Five-year OS rates were 38 ± 8%, 59 ± 7%, 79 ± 8%, 34 ± 12%, and 62 ± 11%, respectively, for patients with myeloid and lymphoid neoplasms, carcinomas, CNS tumors, and "other" SMNs (p < 0.0001). Patients with SMNs after childhood NHL having a reported CPS, mostly mismatch repair disorders, carried a very poor prognosis. Moreover, although outcome was favorable in some subtypes of SMNs after childhood NHL (carcinomas, lymphoid neoplasms), other SMNs such as myeloid neoplasms and CNS tumors had a dismal prognosis.

Bibliografische Daten

OriginalspracheEnglisch
ISSN0887-6924
DOIs
StatusVeröffentlicht - 02.2021
PubMed 32393843